An injection pen for Eli Lilly's weight-loss drug Zepbound is displayed in New York City, Dec. 11, 2023.
Brendan McDermid | Reuters
All doses of By Eli Lilly Popular weight-loss injection Zepbound and diabetes drug Mounjaro are now available in the United States, according to an update to the Food and Drug Administration's drug shortage database on Friday.
An earlier update said there were still shortages of some doses of the treatments. Some doses of Mounjaro have been in short supply since 2022, while doses of Zepbound were added to the FDA's shortage list earlier this year following its approval in the US in November.
Demand for weight-loss and diabetes drugs has outstripped supply for months, pushing Eli Lilly and its rival New Nordisk invest billions to increase manufacturing output.
The FDA update comes a day after Eli Lilly CEO David Ricks told Bloomberg that shortages of Mounjaro and Zepbound would end “very soon.”
“I think we actually plan to exit that process today or tomorrow,” he told the outlet in an interview.
An Eli Lilly spokesperson did not immediately respond to a request for comment on Friday's FDA update.
According to the FDA database, all doses of Novo Nordisk's diabetes shot Ozempic are available in the United States as of Friday. Meanwhile, the FDA said some doses of Novo Nordisk's weight-loss drug Wegovy are in limited supply.
